Please enable Javascript
Elizabeth Plimack, MD, MS, FASCO
Elizabeth Plimack, MD, MS, FASCO, is the Deputy Director of Fox Chase Cancer Center.
Articles by Elizabeth Plimack, MD, MS, FASCO
Gene Mutations as Predictive Biomarkers for Cisplatin-Based Chemotherapy Response in Bladder Cancer
Elizabeth Plimack, MD, MS, FASCO
Muscle Invasive Urothelial Carcinoma
|
September 10, 2024
Dr. Plimack provides an update on the SWOG S1314 trial for MIBC, including four genes predictive of pT0 disease after NAC.
View More
What’s on the Horizon for RCC Treatment and Care?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
View More
RCC Highlights From ASCO GU: Adjuvant Treatment, Immunotherapy, Toxicities, and More
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
View More
KEYNOTE-B61 Study Results and a Focus on Non-Clear Cell Kidney Cancer
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
View More
Longer-Term Follow-Up on Frontline IO and TKI Studies and Impacts to Treatment Selection
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
View More
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
View More
ASCO GU Data Updates in Frontline Kidney Cancer: Was Anything Practice Changing?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
View More
CheckMate 214, KEYNOTE-564, and Updates in Treatment Approaches to nccRCC
Elizabeth Plimack, MD, MS, FASCO
Advanced Renal Cell Carcinoma
|
May 1, 2024
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
View More
Single-Agent ADCs in Urothelial Carcinoma: Where We Stand and Where We Are Going
Elizabeth Plimack, MD, MS, FASCO
Advanced Urothelial Carcinoma
|
December 19, 2023
Dr. Plimack provides a summary of her presentation at the SUO Annual Meeting on the progress of ADCs in UC research.
View More
A “Negative” RCC Trial Informs Treatment Decisions in Refractory Disease
Brian Rini, MD, FASCO
Video Insights
|
August 23, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
View More
KEYNOTE-B61: Putting a Focus on Non-Clear Cell RCC Treatment
Brian Rini, MD, FASCO
Video Insights
|
August 23, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
View More
Drs. Rini, Plimack Discuss the Latest Frontline IO/TKI Data in RCC From the 2023 ASCO® Annual Meeting
Brian Rini, MD, FASCO
Video Insights
|
August 1, 2023
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
View More
Dr. Plimack on Whether Hypomethylating Agents Induce Immune Activation in aUC Resistant to ICI
Elizabeth Plimack, MD, MS, FASCO
Advanced Urothelial Carcinoma
|
April 24, 2023
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
View More
Dr. Elizabeth Plimack on a Hypomethylating Agent Plus Anti-PD-L1 for mUC After Disease Progression
Elizabeth Plimack, MD, MS, FASCO
Advanced Urothelial Carcinoma
|
April 24, 2023
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.
View More